TMCnet News
R-Tech Ueno: Notice of Revisions of Dividend ForecastTOKYO --(Business Wire)-- R-Tech Ueno, Ltd. (JASDAQ:4573): A resolution was passed during the Board of Directors' Meeting held on February 12, 2014 to revise our dividend per share forecast as described below. 1. Reasons for the revisions made to the dividend forecast
We consider the return of profits to shareholders to be one of our
important main issues. We will continue to deliver steady dividend
distributions to our shareholders while considering future business
performance. 2. Revisions to the Dividend Forecast
About R-Tech Ueno, Ltd. R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation", targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. We aim at becoming a "global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors." We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).
|